scholarly journals A Population-Based Cohort Study of Malignancies and Late Mortality in Children Treated by Allogeneic Stem Cell Transplantation for Non-Malignant Conditions

2013 ◽  
Vol 19 (2) ◽  
pp. S152
Author(s):  
Adam Stuart Nelson ◽  
Tracey Anne O'Brien ◽  
Renate Thielbeer ◽  
Claire Vajdic ◽  
Anthony Dodds ◽  
...  
Keyword(s):  
Cohort Study ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Population Based ◽  
Late Mortality

scholarly journals Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Roald Lindås ◽  
Tor Henrik Andersson Tvedt ◽  
Kimberley Joanne Hatfield ◽  
Håkon Reikvam ◽  
Øystein Bruserud
Keyword(s):  
Endothelial Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Acute Gvhd ◽  
Serum Levels ◽  
Population Based ◽  
Biologically Active ◽  
Cell Adhesion Molecule 1

Endothelial cells are involved in the pathogenesis of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. These cells express several molecules that can be detected as biologically active soluble forms; serum levels of these molecules may thereby reflect the functional status of endothelial cells. Furthermore, acute GVHD is an inflammatory reaction and endothelial cells function as local regulators of inflammation. We therefore investigated whether differences in preconditioning/pretransplant serum levels of endothelium-expressed molecules (i.e., endocan, vascular cell adhesion molecule 1 (VCAM-1), and E-selectin) were associated with a risk of posttransplant GVHD. Our study should be regarded as a population-based study of consecutive and thereby unselected patients (n=56). Analysis of this pretreatment endothelium biomarker profile by unsupervised hierarchical clustering identified a subset of patients with increased early nonrelapse mortality. Furthermore, low endocan levels were significantly associated with acute GVHD in the liver and gastrointestinal tract, whereas high VCAM-1 levels were associated with acute GVHD in the skin only. Our study suggests that the preconditioning/pretransplant status of endothelial cells (possibly through altered trafficking of immunocompetent cells) is important for the risk and the organ involvement of later acute GVHD.

Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic Data

2006 ◽  
Vol 24 (36) ◽  
pp. 5750-5762 ◽  
Author(s):  
Ulla M. Saarinen-Pihkala ◽  
Carsten Heilmann ◽  
Jacek Winiarski ◽  
Anders Glomstein ◽  
Jonas Abrahamsson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Lymphoblastic Leukemia ◽  
Population Based ◽  
Pediatric Hematology ◽  
Resistant Disease ◽  
First Relapse

Purpose Our focus was on patients with pediatric acute lymphoblastic leukemia (ALL) who experienced relapse or died without becoming transplantation candidates. The purpose was to outline measures needed to improve the outcome. Patients and Methods We analyzed our population-based 20-year data on 3,385 Nordic children with ALL treated on Nordic Society for Pediatric Hematology and Oncology ALL protocols, and described the flow of these patients through relapses, remissions, and deaths as a result of toxicity, demonstrating where major patient losses occurred. Results In total, 854 patients (25%) had a first and 274 patients (8%) had a second ALL relapse. P for survival after the first relapse was .35 ± .02. The induction mortality (2.2%, primary; 10.3%, first relapse; 26.3%, second relapse) and remission mortality (1%, first complete remission [1CR]; 19%, second CR [2CR]) were significant; transplantation-related mortality (TRM) only represented 15% (69 of 459) of the deaths as a result of toxicity. Of the 766 patients entering 2CR, 29% underwent transplantation (P for survival, .46 ± .04), whereas 71% continued receiving chemotherapy (P for survival, .39 ± .02). Children with stem-cell transplantation indications in 2CR, if they did not undergo transplantation, generally died or had a second relapse. The patient groups that underwent transplantation in 1CR (n = 84), 2CR (n = 220), and ≥ 3CR (n = 62) represented different risk profiles. Those with allogeneic stem-cell transplantation (allo-SCT) in ≥ 3CR (P for survival, .37 ± .07) had an ALL and first relapse with favorable features. Conclusion Major patient losses occurred through mortality as a result of toxicity and resistant disease during the pathways before allo-SCT. After relapse, more patients were lost to mortality as a result of toxicity during conventional chemotherapy compared with TRM. After second relapse, the chance for rescue by allo-SCT in ≥ 3CR was minimal. The question of whether transplantation is recommended after ALL relapse should be carefully addressed, and more efficient relapse protocols should be launched.

scholarly journals Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation

2016 ◽  
Vol 22 (9) ◽  
pp. 1702-1709 ◽  
Author(s):  
Yoshiko Atsuta ◽  
Akihiro Hirakawa ◽  
Hideki Nakasone ◽  
Saiko Kurosawa ◽  
Kumi Oshima ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Causes Of Death ◽  
Late Mortality ◽  
Long Term Survivors

Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases

2016 ◽  
Vol 64 (1) ◽  
pp. 197-202 ◽  
Author(s):  
Adam S. Nelson ◽  
Claire M. Vajdic ◽  
Lesley J. Ashton ◽  
Renate E. Le Marsney ◽  
Ian Nivison-Smith ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Malignant Diseases ◽  
Late Mortality
Sign in / Sign up

Export Citation Format

Share Document